RPL36AL: A Ribosomal Protein HL44 Drug Target and Biomarker (G6166)

Target Name: RPL36AL

NCBI ID: G6166

RPL36AL

RPL36AL: A Ribosomal Protein HL44 Drug Target and Biomarker

Ribosomal protein (RPN) HL44 is a key protein that plays a crucial role in the regulation of gene expression and cell signaling. It is a large nuclear protein that forms a complex with small nucleolar RNA (snRNA) in the cytoplasm of eukaryotic cells. RPN HL44 functions as a scaffold to recruit chromatin-remodeling complexes and to facilitate the transfer of RNA polymerase II to the loading site on the ribosome. It is also involved in the regulation of translation efficiency, stability, and quality.

Recent studies have identified RPN HL44 as a promising drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential of RPN HL44 as a drug target is attributed to its unique structural features, its involvement in multiple cellular processes, and its potential to modulate cellular signaling pathways.

Drugs that target RPN HL44 have the potential to modulate its expression levels and disrupt its functions, leading to therapeutic benefits. Several inhibitors have been shown to interact with RPN HL44 and inhibit its activity. These inhibitors have been tested in a variety of cellular models and have shown to have potential therapeutic applications.

Biomarkers

RPN HL44 has also been identified as a potential biomarker for various diseases. Its expression levels can be affected by various factors, including genetic and environmental factors. The levels of RPN HL44 have been shown to be reduced in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The potential of RPN HL44 as a biomarker is attributed to its stability and its ability to be expressed and processed in a variety of cellular contexts. Its stability has been shown to be affected by various factors, including genetic and environmental factors. The stability of RPN HL44 has also been linked to its role in regulating gene expression and cellular signaling pathways.

Conclusion

In conclusion, RPN HL44 is a promising drug target and biomarker for various diseases. Its unique structural features and involvement in multiple cellular processes make it an attractive target for small molecule inhibitors. Further studies are needed to fully understand the potential of RPN HL44 as a drug target and biomarker, and to develop effective therapies based on these insights.

Protein Name: Ribosomal Protein L36a Like

The "RPL36AL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL36AL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets